LLY vs NVO: Lilly's Dual Agonist Has the Better Drug; Novo Nordisk Has the Better Manufacturing Machine
Eli Lilly and Novo Nordisk share a duopoly over what may be the largest pharmaceutical market in history. GLP-1 drugs have moved from niche diabetes treatments to mainstream weight-loss and cardiovascular medicines — and the addressable market keeps expanding as clinical evidence grows. Both stocks are priced for continued dominance. The question is which company has the stronger moat for the decade ahead.
The Core Difference
Novo Nordisk pioneered GLP-1 drugs. Ozempic and Wegovy are household names in a way pharmaceutical brands rarely become. NVO has 100 years of diabetes expertise, the deepest manufacturing infrastructure for GLP-1 biologics, and a global commercial network that gave Wegovy a head start in the obesity market. Their experience with the supply chain for biologics is genuinely difficult to replicate quickly.
Eli Lilly came second with a pharmacologically superior drug. Mounjaro (tirzepatide) targets both GIP and GLP-1 receptors simultaneously — the dual mechanism produces greater weight loss than semaglutide alone. In head-to-head SURMOUNT trials, tirzepatide showed ~22% body weight reduction vs ~15% for semaglutide. Lilly also has a deeper pipeline outside GLP-1: donanemab for Alzheimer's, a broad oncology portfolio, and immunology drugs. This pipeline diversification is a meaningful risk-management advantage over NVO.
Business Comparison
- Mounjaro/Zepbound: superior efficacy (~22% weight loss)
- Pipeline: oncology, Alzheimer's (donanemab), immunology
- Higher P/E (35–45x) — premium for pipeline breadth
- Manufacturing ramping — supply constraints easing
- US-headquartered, dollar-denominated revenues
- Dividend: ~0.7% yield (growth-oriented)
- Ozempic/Wegovy: first-mover, massive brand recognition
- GLP-1 focused pipeline — fewer non-diabetes drugs
- Lower P/E (25–35x) — slight relative discount
- Manufacturing leader — 30+ years of GLP-1 production
- Denmark-headquartered — forex and regulatory risk
- Dividend: ~1% yield
The Market Is Likely Big Enough for Both
The obesity market alone represents 100M+ eligible US patients. Add cardiovascular prevention indications, kidney disease approvals, and potential Alzheimer's crossover (early GLP-1 data shows cognitive benefits), and the addressable market expands to hundreds of millions globally. Neither LLY nor NVO needs to destroy the other to justify their current market caps — the market is simply large enough that both can grow simultaneously for years.
The real risk to both valuations is competitive: AstraZeneca, Amgen, Roche, and others have GLP-1 or adjacent programs in development. If a once-weekly oral GLP-1 pill from a competitor reaches the market at lower cost, it could undermine the injectable franchise that both LLY and NVO are built on. This is a known risk, priced partially in — but the timeline is uncertain.
Who Should Buy Which
Technical Signals — What to Watch
LLY and NVO move primarily on clinical data, prescription volume reports, and earnings. Quarterly IMS Health / IQVIA prescription data for Mounjaro vs Ozempic market share is the single most important fundamental data point to track between earnings.
- RSI: Both stocks have seen sustained RSI above 70 during GLP-1 demand acceleration phases — the trend can persist much longer than typical overbought signals suggest.
- MACD: NVO MACD has historically led LLY slightly — NVO reports earlier in earnings season and often sets the tone for the GLP-1 sector.
- Volume: FDA approval announcements for new indications (cardiovascular, kidney) drive the largest one-day volume spikes on both names.
APEX scores both stocks daily across RSI, MACD, moving averages, volume, and 52-week position. Updated every market day.
Compare LLY vs NVO Live →